- Recruiting
NCT04017130: Phase 1: Study to Evaluate the Safety, Tolerability, Pharmak & Efficacy of MT-0169 RRMM
Updated: May 26, 2022
A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of MT-0169 in Patients With Relapsed or Refractory Multiple Myeloma or Non-Hodgkin Lymphoma

This will be a Phase 1 Open-Label, dose escalation and expansion study of MT-0169 (an Engineered toxin body (ETB) in patients with relapsed or refractory multiple myeloma or non-Hodgkin lymphoma. MT-0169 is an investigational drug that recognizes and binds to the CD38 receptor, which may be found on the surface of multiple myeloma and non-Hodgkin lymphoma cancer cells. It delivers a dose of a modified toxin that kills these cells.
Sponsor
Multiple Locations
ClinicalTrials.gov Identifier: NCT04017130
Official Title: A Phase 1, Open-Label, Dose-Escalation and Expansion, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of MT-0169 in Patients With Relapsed or Refractory Multiple Myeloma or Non-Hodgkin Lymphoma
First Posted : July 12, 2019
Click here for details on ClinicalTrials.gov
Click here for details on cancer.gov
Drug: MT-0169
Specifically Engineered to Eliminate CD38 Expressing Cells
Locations
United States, California
United States, Florida
United States, Indiana
United States, Minnesota
United States, Pennsylvania
United States, Tennessee